Published in Heart on February 01, 2005
Gender differences and determinants of health related quality of life in coronary patients: a follow-up study. BMC Cardiovasc Disord (2011) 1.02
The hitchhiker's guide to research in clinical biochemistry. Clin Biochem Rev (2010) 0.95
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J (2000) 8.43
Impact of changing diagnostic criteria on incidence, management, and outcome of acute myocardial infarction: retrospective cohort study. BMJ (2003) 1.52
HYPERTENSION and coronary heart disease: classification and criteria for epidemiological studies. World Health Organ Tech Rep Ser (1959) 1.43
Was it a heart attack? Variations in access to and interpretation of troponin assays are wide. BMJ (2002) 1.12
Risk stratification in unstable coronary artery disease--exercise test and troponin T from a gender perspective. FRISC-Study Group. Fragmin during InStability in Coronary artery disease. J Am Coll Cardiol (2000) 1.01
Women and myocardial infarction: agism rather than sexism? Br Heart J (1995) 0.91
Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med (2007) 2.06
Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract (2009) 1.83
The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab (2003) 1.72
Evaluation of glycaemic control limits using the Ames DCA 2000 HbA1c analyser. Diabet Med (1993) 1.72
Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem (1998) 1.39
Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia (2009) 1.30
High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients. Diabet Med (2010) 1.04
HbA1c measurement. J Clin Pathol (2004) 1.02
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) (2008) 0.98
Intra-operative blood glucose measurements. The effect of haematocrit on glucose test strips. Anaesthesia (1994) 0.94
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab (2004) 0.92
Investigation into possible causes of interference in serum testosterone measurement in women. Ann Clin Biochem (2006) 0.92
The relationship between mean glucose and HbA1c in premenopausal women compared with males in the Diabetes Control and Complications Trial. Diabet Med (2007) 0.89
A comparison of methods for the measurement of 8-isoPGF(2α): a marker of oxidative stress. Ann Clin Biochem (2011) 0.88
Evaluation of a latex-enhanced immunoturbidimetric assay for measuring low concentrations of C-reactive protein. Ann Clin Biochem (1998) 0.88
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab (2013) 0.87
The effect of extensive flooding in Hull on the glycaemic control of patients with diabetes. Diabet Med (2011) 0.86
Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf) (2007) 0.85
High-polyphenol chocolate reduces endothelial dysfunction and oxidative stress during acute transient hyperglycaemia in Type 2 diabetes: a pilot randomized controlled trial. Diabet Med (2013) 0.82
Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. Diabet Med (2008) 0.82
Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol (Oxf) (2013) 0.82
Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) (2013) 0.81
The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab (2002) 0.81
Short-term glucose variability in healthy volunteers is not associated with raised oxidative stress markers. Diabetes Obes Metab (2012) 0.81
Biological variation of cardiovascular risk factors in patients with diabetes. Diabet Med (2013) 0.81
Diagnostic performance of using one- or two-HbA1c cut-point strategies to detect undiagnosed type 2 diabetes and impaired glucose regulation within a multi-ethnic population. Diab Vasc Dis Res (2012) 0.80
Dehydroepiandrosterone sulphate interferes with the Abbott Architect direct immunoassay for testosterone. Ann Clin Biochem (2006) 0.78
Stability of creatinine with delayed separation of whole blood and implications for eGFR. Ann Clin Biochem (2007) 0.77
New recommendations in diagnosis of diabetes mellitus from the Department of Health: comparing the old and new. Diabet Med (2010) 0.77
HbA(1c): 'The old order changeth'. Diabet Med (2009) 0.77
The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes. Ann Clin Biochem (2009) 0.77
Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment. Diabet Med (2013) 0.77
Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome. Diabetes Obes Metab (2014) 0.76
UK's diagnostic criteria for diabetes are different from US's. BMJ (1999) 0.75
Low-density lipoprotein particle size in type 2 diabetic patients and age matched controls. Ann Clin Biochem (1994) 0.75
Serum fructosamine/haemoglobin A1 ratio predicts the future changes in haemoglobin A1 in type 2 (non-insulin dependent) diabetic patients. Clin Chim Acta (1991) 0.75
Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change. Diabet Med (2005) 0.75
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement? Diabetes Obes Metab (2010) 0.75
Impaired fasting glucose and impaired glucose tolerance: follow-up rates over 2 years within a primary care setting. Diabet Med (2010) 0.75
Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant. Diabet Med (2011) 0.75
Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls. Horm Metab Res (2011) 0.75